AQR Capital Management LLC Decreases Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

AQR Capital Management LLC lessened its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 20.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 125,995 shares of the company’s stock after selling 33,328 shares during the period. AQR Capital Management LLC owned approximately 0.18% of Kiniksa Pharmaceuticals worth $2,352,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Squarepoint Ops LLC lifted its stake in shares of Kiniksa Pharmaceuticals by 84.0% in the second quarter. Squarepoint Ops LLC now owns 24,845 shares of the company’s stock valued at $464,000 after purchasing an additional 11,344 shares during the period. Rubric Capital Management LP lifted its position in shares of Kiniksa Pharmaceuticals by 10.2% during the 2nd quarter. Rubric Capital Management LP now owns 2,419,103 shares of the company’s stock valued at $45,165,000 after acquiring an additional 223,094 shares during the period. XTX Topco Ltd acquired a new stake in shares of Kiniksa Pharmaceuticals during the 2nd quarter valued at approximately $314,000. Dimensional Fund Advisors LP boosted its stake in shares of Kiniksa Pharmaceuticals by 31.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock worth $12,398,000 after acquiring an additional 157,741 shares in the last quarter. Finally, American Century Companies Inc. grew its holdings in shares of Kiniksa Pharmaceuticals by 33.4% in the 2nd quarter. American Century Companies Inc. now owns 29,226 shares of the company’s stock worth $546,000 after acquiring an additional 7,314 shares during the period. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Stock Up 3.1 %

KNSA opened at $24.47 on Wednesday. The firm has a market cap of $1.74 billion, a P/E ratio of 222.45 and a beta of 0.33. The business’s fifty day simple moving average is $25.37 and its 200 day simple moving average is $21.61. Kiniksa Pharmaceuticals, Ltd. has a 52 week low of $14.12 and a 52 week high of $27.92.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, July 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.03. The company had revenue of $108.30 million for the quarter, compared to analysts’ expectations of $90.60 million. Kiniksa Pharmaceuticals had a negative net margin of 3.10% and a negative return on equity of 7.79%. The firm’s revenue for the quarter was up 51.5% compared to the same quarter last year. During the same period last year, the company earned ($0.02) EPS. As a group, equities analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.29 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on KNSA. Jefferies Financial Group assumed coverage on Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 target price on the stock. Wedbush raised their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an “outperform” rating in a report on Tuesday, July 23rd. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Kiniksa Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $33.60.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,500 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $24.99, for a total transaction of $437,325.00. Following the transaction, the chief operating officer now owns 116,975 shares of the company’s stock, valued at $2,923,205.25. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. In related news, COO Eben Tessari sold 17,500 shares of the company’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $24.99, for a total value of $437,325.00. Following the completion of the transaction, the chief operating officer now directly owns 116,975 shares in the company, valued at approximately $2,923,205.25. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Mark Ragosa sold 24,248 shares of the firm’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $24.79, for a total value of $601,107.92. Following the completion of the sale, the chief financial officer now directly owns 19,253 shares in the company, valued at approximately $477,281.87. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 278,064 shares of company stock valued at $7,165,254. Company insiders own 54.57% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.